Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...

Google Cloud’s Vertex AI, a machine learning (ML) platform, is receiving significant updates. Vertex AI is a tool for enterprise AI development. Unlike consumer-facing AI like Gemini or ChatGPT ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%.

Google Cloud’s latest enhancements to Vertex AI and the Gemini model family offer businesses a comprehensive solution for building, deploying, and managing AI applications with unprecedented ...

An agrivoltaics power plant on the plateau of Guizhou province, southwestern China, has been connected to the grid using Trinasolar’s Vertex N 720W series modules. With total capacity of 67.5MW ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

Complications during pregnancy (or adverse pregnancy outcomes), like gestational diabetes and newly developed high blood ...

Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO in a ...